Across TCGA pan-cancer cohorts, RPL23AP17 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL23AP17’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPL23AP17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL23AP17 is over-expressed in tumor, although a few such as READ and KICH show the opposite, repressed pattern.

KIRC, HNSC, and READ are the cancer types where RPL23AP17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL23AP17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	III,IV	+0.051	.003	6	view →
HNSC	All	All	+0.027	.019	4	view →
READ	Female	All	−0.192	.004	2	view →
COAD	All	IV	+0.125	.029	1	view →
KICH	Female	All	−0.064	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RPL23AP17 RNA expression & survival · all RPL23AP17 data types